Monoclonal antibodies in MS Mechanisms of action

被引：77

作者：

Bielekova, Bibiana ^{[1
]}

Becker, Brenda L. ^{[1
]}

机构：

[1] Natl Inst Neurol Disorders & Stroke, Neuroimmunol Dis Unit, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA

来源：

NEUROLOGY | 2010年 / 74卷 / 01期

关键词：

B-CELL DEPLETION; REGULATORY T-CELLS; REMITTING MULTIPLE-SCLEROSIS; NATURAL-KILLER-CELLS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; LYMPHOCYTIC-LEUKEMIA CELLS; CEREBROSPINAL-FLUID; RHEUMATOID-ARTHRITIS; AUTOIMMUNE-DISEASES; RITUXIMAB THERAPY;

D O I：

10.1212/WNL.0b013e3181c97ed3

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The development of monoclonal antibodies (mAbs) presents an emerging, highly specific therapeutic strategy for the treatment of multiple sclerosis (MS). mAbs target selective molecules and have shown early promise, along with notable risks, in the treatment of MS and other immune-mediated diseases. The mechanism of action of the 4 mAbs under active investigation for MS (natalizumab, rituximab, alemtuzumab, and daclizumab) are reviewed, with a discussion of how mAb interaction with each target antigen may produce direct and indirect effects (proven and hypothesized) on immune cell activity, CNS-related inflammatory processes, and clinical outcomes. NEUROLOGY 2010;74 (Suppl 1):S31-S40

引用

收藏

页码：S31 / S40

页数：10

相关论文

共 83 条

[1] Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses [J].

Agarwal, A ;

Vieira, CA ;

Book, BK ;

Sidner, RA ;

Fineberg, NS ;

Pescovitz, MD .

AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (08) :1357-1360

[2] Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial [J].

Bar-Or, Amit ;

Calabresi, Peter A. J. ;

Arnlod, Douglas ;

Markowitz, Clyde ;

Shafer, Stuart ;

Kasper, Lloyd H. ;

Waubant, Ernmanuelle ;

Gazda, Suzanne ;

Fox, Robert J. ;

Panzara, Michael ;

Sarkar, Neena ;

Agarwal, Sunil ;

Smith, Craig H. .

ANNALS OF NEUROLOGY, 2008, 63 (03) :395-400

[3] Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis [J].

Bielekova, B ;

Catalfamo, M ;

Reichert-Scrivner, S ;

Packer, A ;

Cerna, M ;

Waldmann, TA ;

McFarland, H ;

Henkart, PA ;

Martin, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) :5941-5946

[4] Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β [J].

Bielekova, B ;

Richert, N ;

Howard, T ;

Blevins, G ;

Markovic-Plese, S ;

McCartin, J ;

Würfel, J ;

Ohayon, J ;

Waidmann, TA ;

McFarland, HF ;

Martin, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (23) :8705-8708

[5]

Bielekova B, 2009, ARCH NEUROL-CHICAGO, V66, P483, DOI 10.1001/archneurol.2009.50

[6] Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab [J].

Binder, Mascha ;

Voegtle, Friederike-Nora ;

Michelfelder, Stefan ;

Mueller, Fabian ;

Illerhaus, Gerald ;

Sundararajan, Sangeeth ;

Mertelsmann, Roland ;

Trepel, Martin .

CANCER RESEARCH, 2007, 67 (08) :3518-3523

[7] CD4+CD25+FOXP3+ regulatory t cells increase De novo in kidney transplant patients after immunodepletion with Campath-1H [J].

Bloom, D. D. ;

Chang, Z. ;

Fechner, J. H. ;

Dar, W. ;

Polster, S. P. ;

Pascual, J. ;

Turka, L. A. ;

Knechtle, S. J. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (04) :793-802

[8] Non-FcR-binding, humanized anti-CD3 antibody Hu291 induces apoptosis of human T cells more effectively than OKT3 and is immunosuppressive in vivo [J].

Carpenter, PA ;

Tso, JY ;

Press, OW ;

Yu, XZ ;

Anasetti, C .

TRANSPLANTATION PROCEEDINGS, 2000, 32 (07) :1545-1546

[9] Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project [J].

Carson, Kenneth R. ;

Evens, Andrew M. ;

Richey, Elizabeth A. ;

Habermann, Thomas M. ;

Focosi, Daniele ;

Seymour, John F. ;

Laubach, Jacob ;

Bawn, Susie D. ;

Gordon, Leo I. ;

Winter, Jane N. ;

Furman, Richard R. ;

Vose, Julie M. ;

Zelenetz, Andrew D. ;

Mamtani, Ronac ;

Raisch, Dennis W. ;

Dorshimer, Gary W. ;

Rosen, Steven T. ;

Muro, Kenji ;

Gottardi-Littell, Numa R. ;

Talley, Robert L. ;

Sartor, Oliver ;

Green, David ;

Major, Eugene O. ;

Bennett, Charles L. .

BLOOD, 2009, 113 (20) :4834-4840

[10] Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].

Cartron, G ;

Dacheux, L ;

Salles, G ;

Solal-Celigny, P ;

Bardos, P ;

Colombat, P ;

Watier, H .

BLOOD, 2002, 99 (03) :754-758

← 1 2 3 4 5 6 7 8 9 →